Extended Data Fig. 6: TGR enhances CD8+ tumour-specific antitumour function in vivo.
From: Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy
As depicted in Fig. 6f, congenically marked (CD45.1) C57BL/6 female recipient mice were injected subcutaneously with 1×106 B16-OVA melanoma cells and tumours established for 5 d. 5 ×106 control (black) or TGR (orange) OT-I+ TE were injected intravenously per tumour bearing mouse. Mice receiving no TE were used as controls. 3, 6 and 9 d after tumour inoculation, mice received 200 µg anti-PD-1 antibody or IgG2a isotype control in 100 µl PBS intraperitoneally. a, 21 d after tumour inoculation mice were humanely euthanized, blood was collected, red cells were lysed, and the white blood cell fraction stained for congenic markers. Data are presented as % of donor-derived (CD45.2+) CD8+ T cells as a fraction to total circulating CD8+ T cells and each dot represents an individual mouse (n = 5). Statistical significance was calculated by 2-tailed Student’s t test. * p < 0.05; ** p < 0.01. b, 21 d after tumour inoculation mice were humanely euthanized and the tumour mass was excised. Single cell suspensions were analysed by flow cytometry. The number of host (CD45.1) CD8+ T cells per mg tissue was quantified and each dot represents an individual mouse (n = 5). Statistical significance was calculated by 2-tailed Student’s t test. ns not significant. All error bars show SEM.
